PFE : A high-risk high-reward opportunity
The exponential growth of Pfizer during the COVID era can be attributed significantly to its role as a vaccine producer. However, the current levels of PFE are even lower than the pre-COVID trading price. The current stock price is approaching the lowest levels witnessed during the COVID-induced market crash. Consequently, almost all the increase in price driven by the COVID vaccine narrative is not reflected in the current stock price.
I perceive potential in Pfizer as a robust company at its current valuation.
I have entered the market twice at various levels, resulting in a total position size of approximately 1.85% of my capital. I am contemplating additional purchases to augment the position size to 2.5% of the capital. Will update underneath this post if and when I do so.
At present, my intention is to retain the position until the stock reaches its all-time high, presenting a potential upside move of about 122%.
I perceive potential in Pfizer as a robust company at its current valuation.
I have entered the market twice at various levels, resulting in a total position size of approximately 1.85% of my capital. I am contemplating additional purchases to augment the position size to 2.5% of the capital. Will update underneath this post if and when I do so.
At present, my intention is to retain the position until the stock reaches its all-time high, presenting a potential upside move of about 122%.
Declinazione di responsabilità
Le informazioni ed i contenuti pubblicati non costituiscono in alcun modo una sollecitazione ad investire o ad operare nei mercati finanziari. Non sono inoltre fornite o supportate da TradingView. Maggiori dettagli nelle Condizioni d'uso.